• Users Online: 198
  • Print this page
  • Email this page
Ahead of Print

Retinal vasoproliferative tumor regression after intravitreal aflibercept

1 Department of Ophthalmology, Mackay Memorial Hospital, Taipei, Taiwan
2 Department of Ophthalmology, Mackay Memorial Hospital; Department of Optometry, Mackay Junior College of Medicine, Nursing, and Management; Department of Medicine, Mackay Medical College, Taipei, Taiwan

Correspondence Address:
Shawn H Tsai,
Department of Ophthalmology, Mackay Memorial Hospital, No. 92, Section 2, Zhongshan N. Road, Taipei 10449
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/tjo.tjo_21_22

Retinal vasoproliferative tumors (RVPTs) are rare benign retinal lesions typically located in the inferotemporal peripheral retina. Several treatment options exist for the management of RVPTs, but no consensus has been proposed. There are only a few reports on the use of anti-vascular endothelial growth factor with bevacizumab to treat exudative or neovascular retinal changes secondary to RVPTs. This report describes a 68-year-old female with a history of systemic hypertension that presented with a 2-week history of gradual loss of visual acuity in the right eye. Fundoscopic examination showed a RVPTs with atypical location that had a favorable response to two-intravitreal aflibercept injections 1 month apart, with resulting subretinal fluid absorption and tumor regression.

Print this article
  Search Pubmed for
    -  Chu TW
    -  Tsai SH
    -  Chen LJ
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded26    

Recommend this journal